



# Syschem (India) Limited

Regd. Office & Works : Village Bargodam, Teh. Kalka,  
Distt. Panchkula, Haryana -133302, India.  
CIN : L24219HR1993PLC032195  
Ph.: 7082923502, 7082923506  
E-mail : info@syschem.in, URL : www.syschem.in

REF. NO. SIL/2020-21/126

Dated: 08/02/2021

**BY E-MAIL**

The General Manager,  
Deptt of Corporate Services,  
B S E Limited,  
PJ Tower, 25<sup>th</sup> Floor, Dalal Street  
**MUMBAI - 400 001.**

**Sub: Outcome of Board Meeting.**

Dear Sir/Madam,

Pursuant to the regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the company has approved Unaudited Financial Results for the quarter ended 31<sup>st</sup> of December, 2020, along with Limited Review Report as submitted by the statutory Auditors of the Company in its meeting held on 08<sup>th</sup> of February, 2021. The meeting started at 11:00 A.M. and concluded at 13:45 P.M.

This is for your information and records.

Yours sincerely  
For **Syschem (India) Limited**

  
Naresh Batra  
(Authorized Signatory)



**SYSCHEM (INDIA) LIMITED**

Regd. Office : Village BARGODAM, Tehsil Kalka, Distt. Panchkula (Haryana)  
Website : www.syschem.in CIN : L24219HR1993PLC032195

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2020**

| S. No. | Particulars  | QUARTER ENDED             |                           |                           | NINE MONTHS ENDED         |                           |
|--------|--|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|        |  | 31.12.2020<br>(Unaudited) | 30.09.2020<br>(Unaudited) | 31.12.2019<br>(Unaudited) | 31.12.2020<br>(Unaudited) | 31.12.2019<br>(Unaudited) |
| 1.     | <b>Income from Operations</b>  |                           |                           |                           |                           |                           |
|        | (a) Revenue from Operations - Gross  | 2,002.96                  | 1,918.99                  | 1,751.02                  | 5,108.35                  | 6,446.69                  |
|        | (b) Other Income   | 2.80                      | -                         | 1.39                      | 10.72                     | 58.84                     |
|        | <b>Total Income from Operations</b>  | <b>2,005.76</b>           | <b>1,918.99</b>           | <b>1,752.41</b>           | <b>5,119.07</b>           | <b>6,505.53</b>           |
| 2.     | <b>Expenses</b>  |                           |                           |                           |                           |                           |
|        | (a) Cost of materials consumed   | 1,749.54                  | 1,535.14                  | 1,189.42                  | 4,064.86                  | 5,220.69                  |
|        | (b) Purchase of Stock in Trade   | -                         | 0.00                      | 0.00                      | 0.00                      | 0.00                      |
|        | (c) Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-trade  | (1.29)                    | (9.40)                    | 262.89                    | 8.93                      | (29.88)                   |
|        | (d) Employee benefits expense  | 106.64                    | 98.05                     | 93.99                     | 291.90                    | 233.90                    |
|        | (e) Finance Costs  | 2.88                      | 2.24                      | 0.24                      | 5.27                      | 1.31                      |
|        | (f) Depreciation and amortisation expense  | 56.75                     | 57.47                     | 53.18                     | 170.77                    | 161.21                    |
|        | (g) Excise Duty / GST  | 135.08                    | 173.83                    | 212.12                    | 425.18                    | 813.25                    |
|        | (g) Other Expenses   | 110.58                    | 162.64                    | 98.10                     | 445.97                    | 236.66                    |
|        | <b>Total Expenses</b>  | <b>2,160.18</b>           | <b>2,019.97</b>           | <b>1,909.94</b>           | <b>5,412.88</b>           | <b>6,637.14</b>           |
| 3.     | <b>Profit/(Loss) before exceptional Items and Tax (1-2)</b>  | <b>(154.42)</b>           | <b>(100.98)</b>           | <b>(157.53)</b>           | <b>(293.81)</b>           | <b>(131.61)</b>           |
| 4.     | Exceptional Items  | 0.00                      | 0.00                      | 0.00                      | -                         | 0.00                      |
| 5.     | <b>Profit before tax (3-4)</b>   | <b>(154.42)</b>           | <b>(100.98)</b>           | <b>(157.53)</b>           | <b>(293.81)</b>           | <b>(131.61)</b>           |
| 6.     | <b>Tax Expense</b>   | <b>0.00</b>               | <b>0.00</b>               | <b>0.00</b>               | <b>-</b>                  | <b>0.00</b>               |
|        | for Current  | 0.00                      | 0.00                      | 0.00                      | -                         | 0.00                      |
|        | for Deferred   | (0.00)                    | (0.00)                    | (0.00)                    | -                         | (0.00)                    |
|        | for MAT Credit   | 0.00                      | 0.00                      | 0.00                      | -                         | 0.00                      |
| 7.     | <b>Profit/(Loss) for the period (5-6)</b>  | <b>(154.42)</b>           | <b>(100.98)</b>           | <b>(157.53)</b>           | <b>(293.81)</b>           | <b>(131.61)</b>           |
| 8.     | Share of Profit/(Loss) of associates and joint ventures  | 0.00                      | 0.00                      | 0.00                      | 0.00                      | 0.00                      |
| 9.     | <b>Other Comprehensive Income/(Expense) (net of tax)</b>   | <b>0.00</b>               | <b>0.00</b>               | <b>0.00</b>               | <b>0.00</b>               | <b>0.00</b>               |
|        | Items that will not be reclassified to Profit & Loss   | 0.00                      | 0.00                      | 0.00                      | 0.00                      | 0.00                      |
|        | Items that will be reclassified to Profit & Loss   | 0.00                      | 0.00                      | 0.00                      | 0.00                      | 0.00                      |
| 10.    | <b>Total Comprehensive Income for the period (7+9)<br/>(Comprising Profit &amp; Other Comprehensive Income for the period)</b> | <b>(154.42)</b>           | <b>(100.98)</b>           | <b>(157.53)</b>           | <b>(293.80)</b>           | <b>(131.61)</b>           |
| 11.    | <b>Basic and Diluted Earning Per Share on Net Profit after Tax<br/>(in Rupees)</b>   | <b>(0.72)</b>             | <b>(0.47)</b>             | <b>(0.84)</b>             | <b>(1.36)</b>             | <b>(0.70)</b>             |
| 12.    | <b>Paid up Equity Share Capital (Face value Rs.10/- per share)</b>   | <b>2,154.04</b>           | <b>2,154.04</b>           | <b>1,879.04</b>           | <b>2,154.04</b>           | <b>1,879.04</b>           |

**Notes:**

- The above financial results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 8th February, 2021. The Statutory Auditors have carried out a Limited Audit Review of the above results.
- The Financial Results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of Companies Act, 2013 read with relevant Rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- Segment Reporting as defined in Accounting Standard 17 is not applicable as the Company is engaged in pharmaceutical business segment.
- Previous period / year figures have been regrouped, wherever necessary, in order to make them comparable.

PLACE : CHANDIGARH  
DATED : 08.02.2021



By Order of the Board

*(Signature)*  
(RANJAN JAIN)

WHOLE TIME DIRECTOR  
DIN : 00635274



# STAV & CO

CHARTERED ACCOUNTANTS

HOUSE NO. 3130-P, SECTOR 22-D, CHANDIGARH - 160022

(M) 98880 - 55545, email: cavarinder.chauhan@gmail.com

## LIMITED AUDIT REVIEW

The Board of Directors,  
Syschem (India) Limited,  
Village Bargodam, Tehsil Kalka,  
Distt. Panchkula - 133 302 [Haryana]

SUB :- LIMITED AUDIT REVIEW FOR THE QUARTER ENDED 31.12.2020.

Dear Sirs,

We have reviewed the accompanying statement of Unaudited Financial Results of **Syschem (India) Limited** ("The Company") for the period ended 31<sup>st</sup> December, 2020. The Statement being submitted to the Company pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015 read with SEBI Circular Dated July 5, 2016.

This statement is the responsibility of the Company's management and has been approved by the Board of Directors at its meeting held on 08<sup>th</sup> February, 2021. Our responsibility is to issue a report on these financial statements based on the review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results has been prepared in accordance with applicable Accounting Standards i.e. IND AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015 read with SEBI Circular Dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S T A V & CO**  
**Chartered Accountants**  
**Firm Registration No. 024510C**

*Varinder Singh*  


**(CA VARINDER SINGH)**  
**PARTNER**  
**M.No. 542573**

**Date : 08.02.2021**  
**Place : Chandigarh**

**UDIN : 21 542573 AAAAA H8649**